+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 670 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.

Age: 18Years +All GendersPhase 2
148 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
W

Actively Recruiting

Researchers are evaluating a culturally-tailored home-based physical activity program designed for Hispanic or LatinoLatina adolescent and young adult childhood cancer survivors. These survivors may face long-term effects like weight gain, fatigue, and reduced physical fitness after cancer treatment. The study aims to see if this culturally-relevant program can help increase physical activity and improve overall health compared to using a Fitbit tracker alone. The study has two stages. In Stage 1, 20 Latinx survivors participate in developing the intervention using Fitbit trackers, text messages, social media support, wearable activity devices, and interviews over 9 months. In Stage 2, 170 survivors who do not meet physical activity guidelines are randomized to either the intervention group, which includes Fitbit use, weekly goal-setting, peer support via social media and Zoom meetings, and optional activity partners, or a control group that only uses Fitbit trackers for 12 weeks. The intervention includes an intensive phase with weekly sessions followed by a 4-week maintenance phase. Participants will wear Fitbit trackers daily and engage in goal-setting, peer discussions, and physical activity reminders. Researchers will measure moderate to vigorous physical activity, sedentary time, and health-related quality of life over 12 weeks. Additional evaluations include physiological markers of heart and metabolic health and qualitative interviews to improve the program. The study lasts through the intervention phases with ongoing monitoring and support for participants.

Age: 15Years - 20YearsAll GendersPhase 2
77 locations
P

Actively Recruiting

Researchers are studying MEN2312, a lysine acetyltransferase 6 KAT6 inhibitor, in adults with advanced breast cancer that is not curable. This first-in-human, phase 1 study evaluates MEN2312 alone and in combination with elacestrant to understand its safety and determine the best dose. Participants have specific genetic alterations in their tumors and have received prior endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitor treatment. Participants will be randomly assigned to receive either MEN2312 by itself or MEN2312 combined with elacestrant, both given as oral tablets. The study follows a sequential design and aims to identify dose-limiting toxicities and recommend the phase 2 dose over several months of treatment. This includes monitoring drug levels in the body and how the body processes the medications. During the study, participants will have regular assessments to monitor side effects, tumor response, and overall health. These include evaluating the number of dose-limiting toxicities within the first 28 days and tracking response rates, progression-free survival, and overall survival for up to nine months after treatment ends. Researchers will also measure drug concentration and excretion to better understand the treatment effects and safety over time.

Age: 18Years +All GendersPhase 1
45 locations
L

Actively Recruiting

Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.

Age: 18Years +All GendersPhase 3
118 locations
A

Actively Recruiting

Researchers are conducting a 10-year multi-center, prospective, longitudinal study in the United States to observe immunologic, inflammatory, and laboratory changes in people with phenylketonuria PKU who are treated with Palynziq pegvaliase. The study includes both new users starting pegvaliase within 30 days after enrolling in a related study 165-501 and those who have already been receiving the treatment before enrollment. The goal is to understand long-term immune and inflammatory responses to this treatment. Participants must already be enrolled in the 165-501 study to join this study. They will provide blood samples before dosing every three months for the first three years, then every six months for the remaining study period. Additional blood samples may be taken during safety events as defined in the related 165-501 study protocol, and standard care blood draws are also incorporated. Blood tests will measure phenylalanine levels and various immune and inflammatory markers, which will be processed centrally. During the study, data from this observational study will be combined with data from the 165-501 study to reduce duplicate reporting and lessen the burden on study sites. Participants may withdraw from this study while continuing in the 165-501 study, but not vice versa, to ensure safety monitoring. The research team will evaluate immune and inflammatory responses over up to 10 years of treatment, tracking changes through blood tests and clinical data collection for a comprehensive understanding of long-term effects.

All AgesAll Genders
11 locations
L

Actively Recruiting

This research follows patients with Hemoglobinopathy and Sickle Cell Disease who previously received BEAM-101, a gene-edited cell treatment, in an earlier study. The trial is a long-term observational follow-up to monitor safety and health outcomes over an extended period. It aims to gather important information about the long-term effects and risks after receiving BEAM-101 treatment. Participants in this study have received a single dose of BEAM-101 by intravenous infusion after a conditioning treatment with busulfan. This follow-up study will track their health for 13 years, adding up to 15 years from the initial treatment. Study visits will happen annually for the first 5 years, then every 3 years until year 11, with a final visit at year 15. Additionally, virtual or phone check-ins will occur every 6 months for the first 5 years, then annually thereafter. During the study, participants will undergo regular safety and efficacy assessments to monitor their health, including how well they remain free of severe sickle cell crises and their blood hemoglobin levels. Researchers will review long-term safety data and mortality over the 13 years. The study includes blood tests and other evaluations at scheduled visits and check-ins. Participation will last up to 15 years, with ongoing monitoring to understand the lasting impact of BEAM-101 treatment.

Age: 14Years - 37YearsAll Genders
17 locations
L

Actively Recruiting

Researchers are studying the long-term safety of ciltacabtagene autoleucel cilta-cel, a CAR-T therapy targeting B-cell maturation antigen in patients previously treated for multiple myeloma. The goal is to collect data on delayed side effects and better understand the long-term risks associated with cilta-cel treatment. This study is a phase 4 trial sponsored by Janssen Research & Development, LLC. Participants in this study do not receive any new treatment. Instead, the study monitors individuals who had previously received cilta-cel in company-sponsored clinical trials. The study is divided into two phases the first five years after the last cilta-cel dose, and years six to fifteen after that dose. Follow-up evaluations are conducted at least once per year to check for any delayed adverse events. During the study, participants undergo safety assessments including reviews of adverse events, laboratory tests, physical and neurological examinations. Researchers track outcomes such as new malignancies, neurological or autoimmune disorders, serious infections, and other serious adverse events over a period of up to 15 years. This long-term follow-up helps characterize the safety profile of cilta-cel after treatment completion.

Age: 18Years +All GendersPhase 4
50 locations

1-10 of 670

1